Navigation Links
Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
Date:12/22/2011

GREENWOOD VILLAGE, Colo., Dec. 22, 2011 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE - News) ("Ampio" or the "Company"), a company that discovers and develops new uses for previously approved drugs and new molecular entities ("NMEs"), today announced notification of the granting of a Canadian patent with broad claims directed to: "METHOD OF USING DIKETOPIPERAZINES AND COMPOSITION CONTAINING THEM". The protected compositions contain either DA-DKP, a cyclic dipeptide diketopiperazine, which is the active ingredient of Ampion™, but also extend to many other diketopiperizines.

Dr. David Bar-Or, Ampio's Chief Scientific Officer, noted "The patent also includes claims for these compositions that target clinical treatments for inflammation and inflammatory diseases and conditions, such as disease or condition is acute respiratory distress syndrome, an allergy, arthritis, asthma, bronchitis, a cancer, a cardiovascular disease, Crohn's disease, cystic fibrosis, emphysema, endocarditis, gastritis, gastrointestinal ulceration, inflammatory bowel disease, ischemia, ischemia reperfusion, multiple organ dysfunction syndrome, myocardial infarction, a neoplastic disease, nephritis, pain, pancreatitis, psoriasis, a respiratory infection, sepsis, shock or ulcerative colitis."

Dr. Bar-Or further noted "This patent complements the already extensive and robust portfolio of worldwide issued patents for Ampion™. The mechanism of action of Ampion™, an innate human biological small molecular weight compound, is unique as it not only inhibits the early activation of memory T cells but also affects an upstream event in inflammation by tightening vascular permeability among other effects".

"We believe that multiple inflammatory conditions might benefit from this biological drug" added Dr. Vaughan Clift, Ampio's Chief Regulatory Officer, "and the compa
'/>"/>

SOURCE Ampio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Champions Biotechnology Reports Fiscal 2009 Third Quarter Financial Results
2. Champions Biotechnology, Inc. Establishes UK Subsidiary and Retains General Manager to Expand Its Personalized Oncology Business
3. Champions Biotechnology Partners with Do-Coop Technologies to Advance Its Novel Oncology Compound Into Biomerk Tumorgraft(TM) Testing
4. Champions Biotechnology Reports Fiscal 2009 Full-Year Financial Results
5. Champions Biotechnology to Deploy its Technology to Guide Development of Oncology Therapeutic for Global Biotech Leader
6. Champions Biotechnology to Present at Rodman & Renshaws Eleventh Annual Healthcare Conference
7. Champions Biotechnology and PinnacleCare Enter Into Personalized Oncology Collaboration Agreement
8. Champions Biotechnology Reports Fiscal 2010 First Quarter Financial Results
9. Champions Biotechnology Expands Collaboration to Test Oncology Therapeutic in Biomerk Tumorgrafts(TM)
10. Champions Biotechnology to Present Data at AACR-EORTC 2009 Regarding the Predictability of Biomerk Tumorgraft(TM) Platform to Guide Personalized Cancer Treatment and Accelerate Oncology Drug Development
11. Champions Biotechnology Enters into Licensing Agreement with Yale University and Southern Research Institute for the Repurposing of Bithionol for Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 29, 2014 According to a new market ... global orthobiologics market was valued at USD 3,754.6 million in ... 5,519.9million in 2019at a CAGR of 5.9% from 2013 to ... and above is afflicted by bone and joint disorders, and ... 2020. This has and will continue to increase the demand ...
(Date:8/29/2014)... Pittsburgh, PA (PRWEB) August 29, 2014 ... Chairman, Hub MacDonald, and colleague Koichiro Matsuda, Horiba Scientific, ... JASIS on September 5, 2014. JASIS , Asia’s ... September 3-5, 2014, in Makuhari Messe, Japan. , ... New Tools for Bioanalysis from Single Molecules to Single ...
(Date:8/29/2014)... , Aug. 29, 2014 /PRNewswire/ - iCo Therapeutics ... today reported financial results for the six months ... are expressed in Canadian dollars and presented under ... Quarter 2014 Highlights , Announced top-line ... (VA) primary endpoint for subjects enrolled in the ...
(Date:8/29/2014)... Hills, NY (PRWEB) August 29, 2014 ... Burnt Hills Veterinary Hospital are seeking candidates to participate ... dogs with osteoarthritis. The ultimate goal of this ... donor stem cells into one or two arthritically affected ... treated joints. , Candidates for the current investigational ...
Breaking Biology Technology:Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 2Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 3Fifth Annual U.S. Symposium at JASIS Organized by Pittcon’s Program Chairman Hub MacDonald 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 4Burnt Hills Veterinary Hospital Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis 2
... Only Collagen-Based Filler Proven To Last Through One Year , ... Ortho Dermatologics today announced that the U.S. Food and Drug ... safety data through 12 months for EVOLENCE(R), a collagen-based dermal ... and folds, such as nasolabial folds. , , To ...
... RAMAT GAN, Israel, June 8 EarlySense announced ... cleared for,marketing by the U.S. Food and Drug Administration ... Dutch notified body, in accordance with the,EC-Directive 93/42/EEC. Both ... home, hospital or clinical setting. In November 2007, EarlySense,announced ...
... under the Pacific Ocean, could provide a powerful clean-up ... issue of the journal, Microbiology , Professor Gejiao ... Wuhan, PR China describe how a particular strain of ... effective in removing manganese from solutions, converting it into ...
Cached Biology Technology:Photos: FDA Approves 12-Month Labeling Update for EVOLENCE(R) Collagen-Based Facial Filler 2Photos: FDA Approves 12-Month Labeling Update for EVOLENCE(R) Collagen-Based Facial Filler 3Photos: FDA Approves 12-Month Labeling Update for EVOLENCE(R) Collagen-Based Facial Filler 4EarlySense's EverOn(TM) System Receives FDA Clearance and CE Mark Certification 2
(Date:8/29/2014)... German . ... cycle on Earth and in biological wastewater treatment plants. ... on nitrite as their source of energy. An international ... at the University of Vienna, has now shown that ... of energy. The oxidation of hydrogen with oxygen enables ...
(Date:8/29/2014)... This news release is available in German . ... of chemical signals between organisms is considered the oldest ... social interactions between conspecifics, for example, the sexual attraction ... trigger social responses and to coordinate reproductive behavior in ... at the University of the Algarve in Faro, Portugal, ...
(Date:8/29/2014)... Some species of marine phytoplankton, such as the prolific ... vitamin B1 (thiamine), researchers have discovered. The finding contradicts ... many other eukaryotic microbes depend on scarce supplies of ... really different way to think about the ocean," says ... The ISME Journal paper with CIFAR fellows ...
Breaking Biology News(10 mins):Hydrogen powers important nitrogen-transforming bacteria 2Hydrogen powers important nitrogen-transforming bacteria 3Ready for mating at the right time 2Ready for mating at the right time 3Not all phytoplankton in the ocean need to take their vitamins 2Not all phytoplankton in the ocean need to take their vitamins 3
... that some brain tumours in larvae of the fruit fly ... cells to grow. The removal of some of these genes ... are crucial for tumour development. The study, headed by ICREA ... Science . One of the characteristics of ...
... mankind,s migration from Africa to the New World, and the ... international study that for the first time will dig deep ... a mile) down under 300 meters (about a fifth of ... researchers will look back in time to collect a massive ...
... University of Exeter have developed a new approach to ... up the process of finding vaccines. Dr Andrea ... the university,s Cornwall Campus, has pioneered a simple screen ... gene structures of pathogenic* bacteria. The screen allows ...
Cached Biology News:Some brain tumors mimic the genetic program of germline cells 2Back to the dead (sea, that is) 2Finding new ways to tackle environmental diseases 2
Umbilical cord blood CD19+ B cells, For immunohistochemistry (IHC) Cell Chip with Human Umbilical Cord Blood Monocytes, B Cells and NK Cells...
Umbilical cord blood CD4+ T cells, For immunohistochemistry (IHC) Cell Chip with Human Umbilical Cord Blood MNCs and T Cells...
Human peripheral blood CD56+ NK cells, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Monocytes, B Cells, NK Cells and Stem Cells...
Yeast tRNA 50 l...
Biology Products: